Advanced Solid Tumor

Oncology
162
Pipeline Programs
30
Companies
50
Clinical Trials
29 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
97
53
12
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
741%
Small Molecule
635%
ADC
424%
+ 148 programs with unclassified modality

Competitive Landscape

74 companies ranked by most advanced pipeline stage

M&
11 programs
6
2
2
HER3-DXdPhase 2
PRT3789Phase 21 trial
Ifinatamab deruxtecanPhase 1/2ADC
NiraparibPhase 1/21 trial
BapotulimabPhase 1Monoclonal Antibody1 trial
+6 more programs
Active Trials
NCT03666273Completed60Est. May 2024
NCT06641908RecruitingEst. Apr 2027
NCT06509906Terminated3Est. Dec 2025
+5 more trials
DS
10 programs
5
2
2
HER3-DXdPhase 21 trial
Raludotatug deruxtecanPhase 2ADC1 trial
DS-3939aPhase 1/21 trial
Ifinatamab deruxtecanPhase 1/2ADC5 trials
DS-1471aPhase 11 trial
+5 more programs
Active Trials
NCT06074705Terminated17Est. Jul 2025
NCT01588678Completed32Est. Jun 2014
NCT02983006Completed12Est. Jan 2021
+11 more trials
Qilu Pharmaceutical
9 programs
6
2
1
QLS31905Phase 21 trial
QLC5508Phase 1/21 trial
QLP2117Phase 1/21 trial
QL1604Phase 11 trial
QLF3108Phase 11 trial
+4 more programs
Active Trials
NCT05801094UnknownEst. Dec 2023
NCT06019013UnknownEst. Dec 2025
NCT05884801UnknownEst. Jul 2025
+6 more trials
LaNova Medicines
LaNova MedicinesChina - Shanghai
9 programs
8
1
LM-108Phase 2
LM-102 InjectionPhase 1/21 trial
LM-108Phase 1/21 trial
LM-108Phase 1/21 trial
LM-108Phase 1/21 trial
+4 more programs
Active Trials
NCT05008445TerminatedEst. Feb 2023
NCT05199753CompletedEst. Dec 2024
NCT05518045Active Not RecruitingEst. Mar 2026
+5 more trials
CT
5 programs
2
2
1
LM-108Phase 21 trial
LM-108 injection+Penpulimab+ Oxaliplatin+CapecitabinePhase 1/21 trial
TQB2618 injection and TQB2450 injectionPhase 1/21 trial
TQB3474 injectionPhase 11 trial
TQB3823 tabletsPhase 11 trial
Active Trials
NCT04144855UnknownEst. May 2021
NCT05021367UnknownEst. Oct 2025
NCT06825494RecruitingEst. Sep 2026
+2 more trials
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
4 programs
2
2
DurvalumabPhase 2Monoclonal Antibody1 trial
MEDI5752Phase 22 trials
DS-1103aPhase 1
FPI-2053Phase 11 trial
Active Trials
NCT06147037Recruiting70Est. May 2028
NCT04705818Completed164Est. Jul 2025
NCT05888857Not Yet Recruiting102Est. Sep 2028
+1 more trials
Jazz Pharmaceuticals
3 programs
2
1
LurbinectedinPhase 21 trial
JZP341Phase 11 trial
JZP898Phase 1
Active Trials
NCT05631327Terminated12Est. Apr 2024
NCT05126433Terminated47Est. Dec 2023
Artios Pharma
2 programs
1
1
ART0380Phase 21 trial
ART6043Phase 1/21 trial
Active Trials
NCT05898399Active Not Recruiting220Est. Dec 2026
NCT05798611Terminated36Est. May 2025
InnoCare
InnoCareChina - Beijing
1 program
1
ICP-192Phase 21 trial
Active Trials
NCT05372120Unknown200Est. Jun 2024
GS
Gilead SciencesFOSTER CITY, CA
6 programs
5
1
Sacituzumab Govitecan-hziyPhase 1/2ADC1 trial
AB308Phase 11 trial
DenikitugPhase 11 trial
DenikitugPhase 1
GS-5319Phase 11 trial
+1 more programs
Active Trials
NCT04772989Completed94Est. Aug 2025
NCT05007782Recruiting416Est. Dec 2028
NCT07128303Recruiting178Est. May 2028
+1 more trials
Novartis
4 programs
3
1
IMX-110 combined with TislelizumabPhase 1/2Monoclonal Antibody1 trial
BEZ235Phase 11 trial
BKM120Phase 11 trial
CLR457Phase 11 trial
Active Trials
NCT01195376Completed35Est. Jul 2013
NCT01283503Completed15Est. Oct 2011
NCT02189174Terminated31Est. Nov 2015
+1 more trials
OncoC4
4 programs
3
1
AI-081Phase 1/21 trial
ONC-783Phase 11 trial
ONC-841Phase 11 trial
ONC-841Phase 11 trial
Active Trials
NCT07408258Not Yet RecruitingEst. Jun 2028
NCT06219499WithdrawnEst. Jun 2026
NCT06352359RecruitingEst. Sep 2027
+1 more trials
MediLink Therapeutics
4 programs
1
3
YL201Phase 1/21 trial
YL201 for InjectionPhase 1/21 trial
YL242Phase 1/21 trial
YL217Phase 11 trial
Active Trials
NCT06859762RecruitingEst. Jul 2027
NCT05434234RecruitingEst. Oct 2027
NCT06057922RecruitingEst. Oct 2028
+1 more trials
Jacobio Pharmaceuticals
3 programs
3
JAB-21822Phase 1/21 trial
JAB-23E73Phase 1/21 trial
JAB-3068Phase 1/2
Active Trials
NCT05002270CompletedEst. Feb 2025
NCT06959615RecruitingEst. Aug 2027
Xilio Therapeutics
3 programs
3
XTX202Phase 1/21 trial
XTX301Phase 1/21 trial
vilastobartPhase 1/21 trial
Active Trials
NCT05052268CompletedEst. Mar 2025
NCT05684965RecruitingEst. Feb 2027
NCT04896697Recruiting136Est. Mar 2026
Philogen
2 programs
1
1
F16IL2 in combination with doxorubicinPhase 1/21 trial
IL12-L19L19Phase 11 trial
Active Trials
NCT04471987Recruiting80Est. Dec 2026
NCT01131364Terminated29Est. Dec 2012
SpringWorks Therapeutics
2 programs
1
1
MirdametinibPhase 1/2Small Molecule1 trial
SW-682Phase 11 trial
Active Trials
NCT06251310Recruiting186Est. Jun 2030
NCT05580770Terminated23Est. Jan 2025
Ipsen
IpsenChina - Tianjin
2 programs
2
IPN01195Phase 1/21 trial
IPN01203Phase 1/21 trial
Active Trials
NCT06833008Recruiting85Est. Oct 2028
NCT07213830Recruiting102Est. Jul 2032
Ascendis Pharma
2 programs
2
TransCon IL-2 β/γPhase 1/21 trial
TransCon TLR7/8 AgonistPhase 1/21 trial
Active Trials
NCT05081609Active Not Recruiting320Est. Aug 2029
NCT04799054Terminated188Est. Dec 2025
AB
1 program
1
AP402Phase 1/21 trial
Active Trials
NCT06669975RecruitingEst. Dec 2027
Treadwell Therapeutics
1 program
1
CFI-402257Phase 1/21 trial
Active Trials
NCT05251714Active Not RecruitingEst. Aug 2026
Eisbach Bio
1 program
1
EIS-12656Phase 1/21 trial
Active Trials
NCT06525298RecruitingEst. Dec 2027
H
1 program
1
Fruquintinib in Combination with SintilimabPhase 1/2Monoclonal Antibody1 trial
Active Trials
NCT03903705Completed348Est. Dec 2024
Eikon Therapeutics
Eikon TherapeuticsCA - Millbrae
1 program
1
IMP1734Phase 1/21 trial
Active Trials
NCT06253130Recruiting70Est. Dec 2026
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
JAB-3068Phase 1/21 trial
Active Trials
NCT04721223Completed12Est. Dec 2023
KSQ Therapeutics
1 program
1
KSQ-001EXPhase 1/21 trial
Active Trials
NCT06237881Active Not RecruitingEst. Jan 2029
Centessa Pharmaceuticals
1 program
1
LB101Phase 1/21 trial
Active Trials
NCT05821777Terminated25Est. Sep 2025
Lantern Pharma
Lantern PharmaDALLAS, TX
1 program
1
LP-184Phase 1/21 trial
Active Trials
NCT05933265Recruiting175Est. Sep 2025
Rain Oncology
1 program
1
MilademetanPhase 1/21 trial
Active Trials
NCT06090318WithdrawnEst. May 2023
Pathios Therapeutics
1 program
1
PTT-4256Phase 1/21 trial
Active Trials
NCT06634849Recruiting30Est. Oct 2027

+44 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Daiichi SankyoIfinatamab deruxtecan
Daiichi SankyoIfinatamab deruxtecan
AmgenPembrolizumab
AmgenPembrolizumab
Daiichi SankyoIfinatamab deruxtecan
AstraZenecaMEDI5752
Merck & Co.PRT3789
Chia Tai TianQing Pharmaceutical GroupLM-108
Daiichi SankyoRaludotatug deruxtecan
Qilu PharmaceuticalQLS31905
Daiichi SankyoHER3-DXd
Artios PharmaART0380
Daiichi SankyoIfinatamab deruxtecan
Jazz PharmaceuticalsLurbinectedin
InnoCareICP-192

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 6,382 patients across 50 trials

NCT06925737Daiichi SankyoIfinatamab deruxtecan

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

Start: May 2025Est. completion: Jan 20311,440 patients
Phase 3Recruiting
NCT06644781Daiichi SankyoIfinatamab deruxtecan

A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

Start: Mar 2025Est. completion: Nov 2029510 patients
Phase 3Recruiting
NCT06430866AmgenPembrolizumab

Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)

Start: Sep 2024Est. completion: Dec 2026154 patients
Phase 3Recruiting
NCT06311721AmgenPembrolizumab

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

Start: Sep 2024Est. completion: May 2028315 patients
Phase 3Active Not Recruiting
NCT06203210Daiichi SankyoIfinatamab deruxtecan

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

Start: May 2024Est. completion: Feb 2029540 patients
Phase 3Recruiting
NCT05888857AstraZenecaMEDI5752

MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors.

Start: Sep 2025Est. completion: Sep 2028102 patients
Phase 2Not Yet Recruiting
NCT06682806Merck & Co.PRT3789

A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

Start: Jun 2025Est. completion: Jan 20266 patients
Phase 2Terminated
NCT06873854Chia Tai TianQing Pharmaceutical GroupLM-108

A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours

Start: Mar 2025Est. completion: Jan 2030
Phase 2Not Yet Recruiting
NCT06660654Daiichi SankyoRaludotatug deruxtecan

A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)

Start: Jan 2025Est. completion: Sep 2027200 patients
Phase 2Recruiting
NCT06446388Qilu PharmaceuticalQLS31905

Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors

Start: Jun 2024Est. completion: Dec 2027
Phase 2Not Yet Recruiting
NCT06172478Daiichi SankyoHER3-DXd

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Start: Feb 2024Est. completion: Oct 2028740 patients
Phase 2Recruiting
NCT05798611Artios PharmaART0380

Study of ART0380 in Patients With Biologically Selected Solid Tumors

Start: Sep 2023Est. completion: May 202536 patients
Phase 2Terminated
NCT05280470Daiichi SankyoIfinatamab deruxtecan

Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Start: Mar 2022Est. completion: Dec 2026187 patients
Phase 2Active Not Recruiting
NCT05126433Jazz PharmaceuticalsLurbinectedin

Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors

Start: Mar 2022Est. completion: Dec 202347 patients
Phase 2Terminated
NCT05372120InnoCareICP-192

A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations

Start: Dec 2021Est. completion: Jun 2024200 patients
Phase 2Unknown
NCT04705818AstraZenecaDurvalumab

Combining Epigenetic And Immune Therapy to Beat Cancer.

Start: Jul 2021Est. completion: Jul 2025164 patients
Phase 2Completed
NCT07213830IpsenIPN01203

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies

Start: Feb 2026Est. completion: Jul 2032102 patients
Phase 1/2Recruiting
NCT07256782Qilu PharmaceuticalQLC5508

A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors

Start: Oct 2025Est. completion: May 2028
Phase 1/2Recruiting
NCT07197827MediLink TherapeuticsYL242

A Study of YL242 in Subjects With Advanced Solid Tumors

Start: Sep 2025Est. completion: Nov 2028
Phase 1/2Recruiting
NCT06682780LaNova MedicinesLM-2417

A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours

Start: Sep 2025Est. completion: Dec 2029
Phase 1/2Recruiting
NCT06863272Daiichi SankyoIfinatamab deruxtecan

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

Start: Jul 2025Est. completion: Feb 2030360 patients
Phase 1/2Recruiting
NCT06911827Qilu PharmaceuticalQLP2117

A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients

Start: May 2025Est. completion: Dec 2028
Phase 1/2Recruiting
NCT06669975AP BiosciencesAP402

A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors

Start: Apr 2025Est. completion: Dec 2027
Phase 1/2Recruiting
NCT06825494Chia Tai TianQing Pharmaceutical GroupLM-108 injection+Penpulimab+ Oxaliplatin+Capecitabine

Clinical Studies for the Treatment of Advanced Solid Tumors

Start: Apr 2025Est. completion: Sep 2026
Phase 1/2Recruiting
NCT06635785OncoC4AI-081

Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

Start: Mar 2025Est. completion: Dec 2027
Phase 1/2Recruiting
NCT06833008IpsenIPN01195

A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours

Start: Mar 2025Est. completion: Oct 202885 patients
Phase 1/2Recruiting
NCT06959615Jacobio PharmaceuticalsJAB-23E73

A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration

Start: Nov 2024Est. completion: Aug 2027
Phase 1/2Recruiting
NCT06634849Pathios TherapeuticsPTT-4256

An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1).

Start: Nov 2024Est. completion: Oct 202730 patients
Phase 1/2Recruiting
NCT06525298Eisbach BioEIS-12656

EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors

Start: Sep 2024Est. completion: Dec 2027
Phase 1/2Recruiting
NCT06249048Strand TherapeuticsSTX-001

Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

Start: May 2024Est. completion: Nov 2028
Phase 1/2Recruiting
NCT06237881KSQ TherapeuticsKSQ-001EX

A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

Start: Jan 2024Est. completion: Jan 2029
Phase 1/2Active Not Recruiting
NCT06187402LaNova MedicinesLM-24C5

A Study of LM-24C5 For Advanced Solid Tumors

Start: Dec 2023Est. completion: Dec 2026
Phase 1/2Recruiting
NCT06253130Eikon TherapeuticsIMP1734

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

Start: Dec 2023Est. completion: Dec 202670 patients
Phase 1/2Recruiting
NCT06057922MediLink TherapeuticsYL201 for Injection

A Study YL201 in Patients With Selected Advanced Solid Tumors

Start: Sep 2023Est. completion: Oct 2028
Phase 1/2Recruiting
NCT05875168Daiichi SankyoDS-3939a

First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

Start: Aug 2023Est. completion: Feb 2027540 patients
Phase 1/2Recruiting
NCT05898399Artios PharmaART6043

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients

Start: Jun 2023Est. completion: Dec 2026220 patients
Phase 1/2Active Not Recruiting
NCT05491083AdagenePembrolizumab & ADG106

Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer

Start: Jun 2023Est. completion: Dec 202651 patients
Phase 1/2Recruiting
NCT05933265Lantern PharmaLP-184

Study of LP-184 in Patients With Advanced Solid Tumors

Start: Jun 2023Est. completion: Sep 2025175 patients
Phase 1/2Recruiting
NCT06090318Rain OncologyMilademetan

Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss

Start: May 2023Est. completion: May 2023
Phase 1/2Withdrawn
NCT05684965Xilio TherapeuticsXTX301

XTX301 in Patients With Advanced Solid Tumors

Start: May 2023Est. completion: Feb 2027
Phase 1/2Recruiting
NCT05103345PharmaronSGN1

Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor

Start: Apr 2023Est. completion: Jun 2028
Phase 1/2Recruiting
NCT05821777Centessa PharmaceuticalsLB101

A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors

Start: Mar 2023Est. completion: Sep 202525 patients
Phase 1/2Terminated
NCT05580770SpringWorks TherapeuticsMirdametinib

Mirdametinib + BGB-3245 in Advanced Solid Tumors

Start: Feb 2023Est. completion: Jan 202523 patients
Phase 1/2Terminated
NCT05840835NovartisIMX-110 combined with Tislelizumab

Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors

Start: Feb 2023Est. completion: Jan 202460 patients
Phase 1/2Unknown
NCT05388435SK Life ScienceSKL27969

Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients

Start: Sep 2022Est. completion: Mar 2024
Phase 1/2Terminated
NCT05518045LaNova MedicinesLM-108

A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors

Start: Aug 2022Est. completion: Mar 2026
Phase 1/2Active Not Recruiting
NCT05251714Treadwell TherapeuticsCFI-402257

CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer

Start: May 2022Est. completion: Aug 2026
Phase 1/2Active Not Recruiting
NCT05255484LaNova MedicinesLM-108

Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours

Start: May 2022Est. completion: Oct 2023
Phase 1/2Terminated
NCT05434234MediLink TherapeuticsYL201

A Study of YL201 in Patients With Advanced Solid Tumors

Start: May 2022Est. completion: Oct 2027
Phase 1/2Recruiting
NCT05188664LaNova MedicinesLM-302

Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Start: May 2022Est. completion: Nov 2023
Phase 1/2Completed

Related Jobs in Oncology

Cell Therapy Account Manager（北陸）

Gilead Sciences
Japan - Tokyo
Just now

Leo Cancer Care: Senior In-House Counsel/General Counsel

Leo Cancer Care
Middleton, Wisconsin
1h ago

Summer Intern - Computational Chemistry & Artificial Intelligence

Arvinas
Remote
3h ago

Executive Director, I.T.- Head of Security Architecture, Engineering, and Delivery

Gilead Sciences
United States - California - Foster City
17h ago
$281K - $364K/yr

Sr Research Associate, Analytical Operations

Gilead Sciences
United States - California - Oceanside
17h ago
$86K - $112K/yr

Associate Director, Insights & Analytics Platform Technology Lead

Gilead Sciences
United States - California - Foster City
17h ago
$196K - $253K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

29 actively recruiting trials targeting 6,382 patients
30 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Solid Tumors(158)